enfortumab vedotin

Overview

Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) designed to target Nectin-4 (also known as PVRL4), a cell adhesion molecule overexpressed on the surface of various epithelial tumor cells, most notably in urothelial carcinoma and triple-negative breast cancer. The drug consists of a fully human anti-Nectin-4 monoclonal antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxic agent. Upon binding to Nectin-4 on tumor cell surfaces, the ADC is internalized, the linker is cleaved by lysosomal proteases, and MMAE is released intracellularly to inhibit tubulin polymerization and induce apoptosis.

Enfortumab vedotin received regulatory approval for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received platinum-containing chemotherapy and a programmed death receptor-1 (PD-1) or CD274 molecule (PD-L1) inhibitor. Its clinical development has since expanded into earlier lines of therapy, perioperative settings, and combination regimens with checkpoint inhibitors such as pembrolizumab, reflecting the drug's broad potential in Nectin-4-expressing malignancies.

Recent Publications Summary

Recent publications have focused on enfortumab vedotin in both perioperative and first-line metastatic urothelial cancer settings, most often in combination with pembrolizumab. In a phase 3 randomized trial of cisplatin-eligible muscle-invasive bladder cancer, neoadjuvant enfortumab vedotin-pembrolizumab followed by cystectomy and adjuvant enfortumab vedotin plus pembrolizumab was compared with standard neoadjuvant cisplatin-gemcitabine plus cystectomy, with event-free survival as the primary endpoint and overall survival and pathological complete response as key secondary endpoints 42485627Jul. A related review also highlighted perioperative enfortumab vedotin and pembrolizumab as an emerging approach in bladder cancer, particularly for patients in whom perioperative strategies may improve outcomes 41707170Feb.

In metastatic urothelial carcinoma, several studies examined real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab, reflecting its role as a standard first-line regimen. A multicenter retrospective cohort across 25 German hospitals reported an overall response rate of 50.2%, with median progression-free survival of 10.2 months and 12-month and 24-month overall survival rates of 71.9% and 60.6%, respectively 42437411Jul. Another real-world study compared first-line enfortumab vedotin plus pembrolizumab with gemcitabine plus cisplatin in metastatic urothelial carcinoma, and a separate analysis compared avelumab maintenance after platinum-based chemotherapy with enfortumab vedotin plus pembrolizumab, underscoring ongoing efforts to define the relative effectiveness of current first-line strategies 42384383Jul42373274Jun.

Additional publications extended interest in enfortumab vedotin to upper tract urothelial carcinoma and to treatment sequencing questions. A case-based report described a pathologic complete response after enfortumab vedotin plus pembrolizumab in node-positive upper tract urothelial carcinoma, while noting that the optimal duration of therapy and the role of consolidative surgery after complete response remain unclear 42049426Apr. Real-world efficacy has also been evaluated in Japanese patients with metastatic urothelial carcinoma using EV-301 trial eligibility stratification and restricted mean survival time analysis, again aiming to understand how outcomes with enfortumab vedotin translate outside clinical trials 41603536Jan.

What Changes, What Holds

1. Perioperative use now looks like a plausible curative-intent strategy, not just metastatic therapy
NEW DIRECTION Neoadjuvant and adjuvant enfortumab vedotin with pembrolizumab move the drug into muscle-invasive bladder cancer around cystectomy, extending the baseline’s metastatic approval into a setting where the goal is event-free and overall survival improvement rather than disease control alone 42485627Jul. That does not displace the established mechanism or metastatic role, but it does broaden the clinical identity of EV into perioperative management and raises the question of how much surgery-centered benefit it can add beyond cisplatin-based chemotherapy.

2. First-line EV plus pembrolizumab is becoming the benchmark, but comparative positioning remains unsettled
REINFORCES Real-world outcomes support the baseline’s statement that EV with pembrolizumab has become a standard first-line regimen in metastatic urothelial carcinoma, with effectiveness and survival that are now being measured outside trials 42437411Jul. The comparative studies against gemcitabine-cisplatin and against avelumab maintenance do not overturn the baseline; instead, they show that the important remaining issue is where this regimen sits relative to other first-line strategies and sequencing choices.

3. Responses in upper tract disease and post-response surgery remain promising but unresolved
NEW DIRECTION A pathologic complete response in node-positive upper tract urothelial carcinoma extends EV plus pembrolizumab into a less established urothelial subset, which the Overview does not specifically cover as a distinct role 42049426Apr. The report also highlights an unresolved practical problem: after a complete response, the duration of therapy and the value of consolidative surgery are still unclear. The Japanese real-world analysis mainly strengthens external validity in metastatic disease, but the sequencing and post-response questions are the more consequential new issues.

Overview update candidates: perioperative EV plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer; real-world first-line effectiveness of EV plus pembrolizumab and ongoing comparative positioning versus other standards; upper tract urothelial carcinoma response and uncertainty about therapy duration/consolidative surgery after complete response.